A PYMNTS Company

Switzerland: Novartis parting with GlaxoSmitheKline for US$13b

By  |  March 27, 2018

Swiss pharmaceutical firm Novartis is selling its stake in a consumer healthcare joint venture with GlaxoSmithKline to the British company for US$13 billion.

    Get the Full Story

    Complete the form to unlock this article and enjoy unlimited free access to all PYMNTS content — no additional logins required.

    yesSubscribe to our daily newsletter, PYMNTS Today.

    By completing this form, you agree to receive marketing communications from PYMNTS and to the sharing of your information with our sponsor, if applicable, in accordance with our Privacy Policy and Terms and Conditions.

    The joint venture was formed in 2015 and Novartis holds a 36.5% stake.

    Novartis CEO Vas Narasimhan said in a statement Tuesday, March 27, that it “is progressing well,” but “the time is right for Novartis to divest a non-core asset at an attractive price.”

    Novartis said the sale will be a cash transaction, and is subject to the approval of GSK shareholders. The four Novartis-appointed directors on the joint venture’s 11-member board will step down when the sale is completed.

    Full Content: USA Today

    Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.